August 12, 2024 03:43 PM EDT
Pharma
Law

J&J re­ceives sup­port for $6.5B talc set­tle­ment — re­port

Nicole DeFeudis

Editor

Ovar­i­an can­cer claimants have vot­ed in fa­vor of John­son & John­son’s pro­posed $6.5 bil­lion talc set­tle­ment plan, clear­ing the way for its sub­sidiary to file …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times